Effect of methotrexate on serum levels of IL-22 in patients with psoriasis

European Journal of Dermatology

Volumn 21, Issue 4, 2011, Pages 501-504

  Meephansan, Jitlada ^a   Ruchusatsawat, Kriangsak ^b   Sindhupak, Wannasri ^a   Thorner, Paul Scott ^a,c   Wongpiyabovorn, Jongkonnee ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Interleukin 22; Methotrexate; Psoriasis

Indexed keywords

INTERLEUKIN 22; METHOTREXATE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS SEVERITY INDEX;

ADULT; DERMATOLOGIC AGENTS; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 80053000871     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1335     Document Type: Article

References (25)

1. Zhang K, Liu R, Yin G, Li X, Li J, Zhang J. Differential cytokine secretion of cultured bone marrow stromal cells from patients with psoriasis and healthy volunteers. Eur J Dermatol 2010; 20: 49-53.
2. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G. Chemokine networks in inflammatory skin diseases. Eur J Dermatol 2004; 14: 203-8.
3. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol 2007; 28: 51-7.
4. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-9.
5. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-9.
6. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87: 523-36.
7. Wolk K, Sabat R. Interleukin-22: a novel T-and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17: 367-80.
8. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-94.
9. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009; 29: 210-4.
10. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004; 50: 301-9.
11. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114: 154-63.
12. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-8.
13. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 502-8.
14. Sigmundsdottir H, Johnston A, Gudjonsson JE, Bjarnason B, Valdimarsson H. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol 2004; 13: 426-34.
15. Torres-Alvarez B, Castanedo-Cazares JP, Fuentes-Ahumada C, Moncada B. The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 334-9.
16. Yazici AC, Tursen U, Apa DD, et al. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res 2005; 297: 249-55.
17. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin Exp Rheumatol 2008; 26: 317-23.
18. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 1189-96.
19. Piskin G, Heydendael VM, de Rie MA, Bos JD, Teunissen MB. Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. Arch Dermatol Res 2003; 294: 559-62.
20. Rentenaar RJ, Heydendael VM, van Diepen FN, de Rie MA, ten Berge IJ. Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. J Clin Immunol 2004; 24: 361-9.
21. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
22. Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci 2010; 58: 225-7.
23. Boniface K, Guignouard E, Pedretti N, et al. A role for T cellderived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007; 150: 407-15.
24. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573-85.
25. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-9.